Leeds Cancer Centre at St. James's University Hospital
Welcome,         Profile    Billing    Logout  
 17 Trials 
32 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Twelves, Chris
ELAINE 3, NCT05696626: Evaluation of Lasofoxifene Combined with Abemaciclib Compared with Fulvestrant Combined with Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer with an ESR1 Mutation

Recruiting
3
400
Europe, Canada, US, RoW
Lasofoxifene in combination with abemaciclib, Fulvestrant in combination with abemaciclib
Sermonix Pharmaceuticals Inc.
Metastatic Breast Cancer
06/25
06/26
NCT04796324 / 2020-004610-35: Anti-tumor Effect of Ixabepilone in Metastatic Breast Cancer (mBC) Selected by the Ixabepilone DRP.

Recruiting
2
60
Europe
Ixabepilone Injection
Allarity Therapeutics, Allarity Therapeutics
Metastatic Breast Cancer
10/24
11/25
Cook, Gordon
FiTNEss, NCT03720041 / 2018-003590-10: Myeloma XIV: Frailty-adjusted Therapy in Transplant Non-Eligible Patients With Newly Diagnosed Multiple Myeloma

Recruiting
3
740
Europe
R1: Ixazomib, Lenalidomide, Dexamethasone (IRD) induction therapy - reactive arm, Ninlaro, Revlimid, R1: Ixazomib, Lenalidomide, Dexamethasone (IRD) induction therapy - adaptive arm, R2: Lenalidomide plus placebo maintenance, R2: Lenalidomide + ixazomib maintenance
University of Leeds, Cancer Research UK, Takeda, Celgene
Multiple Myeloma
12/24
12/24
ACCoRd, NCT03562169: The Role of Ixazomib in Autologous Stem Cell Transplant in Relapsed Myeloma - Myeloma XII

Recruiting
3
406
Europe
Ixazomib, thalidomide, & dexamethasone (ITD) re-induction, Conventional autologous stem cell transplant (ASCT-con), Augmented autologous stem cell transplant (ASCT-aug), ITD consolidation and ixazomib maintenance vs. No further therapy
University of Leeds, Cancer Research UK, Takeda
Multiple Myeloma
03/26
03/27
iinnovate-1, NCT03215030: A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma

Active, not recruiting
1/2
336
Europe, Canada, Japan, US, RoW
Modakafusp alfa, TAK-573, TEV-48573, Dexamethasone
Takeda
Multiple Myeloma
02/24
11/24
iinnovate-3, NCT05590377 / 2022-002169-14: A Study of Modakafusp Alfa Together With Daratumumab Adults With Relapsed or Refractory Multiple Myeloma

Completed
1/2
15
Europe, Canada, US, RoW
Modakafusp Alfa, TAK-573, Daratumumab
Takeda, Takeda Development Center Americas, Inc.
Multiple Myeloma
05/24
05/24
EMN-COVID, NCT04492371: COVID-19 Infection and Multiple Myeloma

Completed
N/A
1054
Europe, RoW
Stichting European Myeloma Network, Fondazione EMN Italy Onlus
Multiple Myeloma, Covid19, Corona Virus Infection
08/22
03/24
Bowen, David
EUMDS, NCT00600860: A Prospective, Multicentre European Registry for Newly Diagnosed Patients With Myelodysplastic Syndromes

Recruiting
N/A
4000
Europe, RoW
No interventions
Radboud University Medical Center
Myelodysplastic Syndromes (MDS)
12/22
06/23
NCT05855252: PRECISION-TBI - An Observational Study of Patients With Moderate to Severe Traumatic Brain Injury

Recruiting
N/A
300
RoW
No intervention
Australian and New Zealand Intensive Care Research Centre
Trauma, Brain
04/25
07/25
STEPCARE, NCT05564754 / ACTRN12623001057673: Sedation, Temperature and Pressure After Cardiac Arrest and Resuscitation

Recruiting
N/A
3500
Europe, RoW
Feedback-controlled temperature device, High MAP, Deep sedation, Fever control without a device, Low MAP, Minimal sedation
Region Skane, Lund University, Lund, Sweden, Copenhagen Trial Unit, Center for Clinical Intervention Research, The George Institute for Global Health, Australia, HUS Helsinki University Hospitals, Helsinki, Finland, Medical Research Institute of New Zealand Rangahautia Te Ora, Wellington, New Zealand
Cardiac Arrest With Successful Resuscitation, Hypoxia, Brain
12/25
06/26
ANTHONEY, Alan
SAFIR-ABC10, NCT05615818: Personalized Medicine for Advanced Biliary Cancer Patients

Recruiting
3
800
Europe
Futibatinib, Ivosidenib, Tibsovo, Zanidatamab, Trastuzumab, Zercepac, Neratinib, Nerlynx, Encorafenib, Braftovi, Binimetinib, Mektovi, Niraparib, Zejula, Cisplatin, Gemcitabine
UNICANCER, Cancer Research UK & UCL Cancer Trials Centre, Belgian Group of Digestive Oncology, National Cancer Institute, France, Cancer Research UK, Taiho Oncology, Inc., Servier, Zymeworks BC Inc., Accord Healthcare, Inc., Pierre Fabre Medicament
Biliary Tract Neoplasms
06/27
06/28
ST101-101, NCT04478279 / 2019-004213-13: A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors

Active, not recruiting
1/2
125
Europe, US
ST101, Temozolomide, Radiation
Sapience Therapeutics
Glioblastoma, Melanoma Stage IV, Breast Cancer, Prostate Cancer, Glioblastoma Multiforme, GBM, Brain Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Prostate Cancer, Melanoma Recurrent, Prostate Cancer Metastatic, Recurrent Glioblastoma, Newly Diagnosed Glioblastoma
12/24
12/25
Person, Contact
PATCH, NCT00303784 / 2005-001030-33: Prostate Adenocarcinoma TransCutaneous Hormones

Recruiting
3
2200
Europe
Goserelin, Zoladex, Estradiol, FemSeven
University College, London, Medical Research Council
Anemia, Cardiovascular Complications, Hot Flashes, Osteoporosis, Prostate Cancer
08/21
08/21
UKALL14, NCT01085617 / 2009-012717-22: Standard Chemotherapy With or Without Nelarabine or Rituximab in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Active, not recruiting
3
1033
NA
palifermin, rituximab, cyclophosphamide, cytarabine, daunorubicin hydrochloride, etoposide, fludarabine phosphate, imatinib mesylate, melphalan, mercaptopurine, methotrexate, nelarabine, pegaspargase, vincristine sulfate, allogeneic hematopoietic stem cell transplantation, total-body irradiation
University College, London
Leukemia, Mucositis, Oral Complications
12/24
12/25
STAMPEDE, NCT00268476: Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy

Active, not recruiting
2/3
11992
Europe
Celecoxib, Celebrex, Docetaxel, Taxotere, Prednisolone, Prednisone, ADT, Androgen Deprivation Therapy, Zoledronic Acid, Zometa, Abiraterone, Zytiga, Radiotherapy to the prostate, RT, Enzalutamide, Xtandi, Metformin, Metformin Hydrochloride, Transdermal Oestradiol, Progynova TS
Medical Research Council
Prostate Cancer
03/26
12/30
NCT00589017: Tamoxifen in Treating Patients With Metastatic Bladder Cancer That Did Not Respond to Previous Chemotherapy

Recruiting
2
75
US, Europe
tamoxifen citrate, immunohistochemistry staining method, laboratory biomarker analysis
Baylor College of Medicine
Bladder Cancer
07/10
 
NCT03412643: Study of Neoadjuvant Chemotherapy Plus Trastuzumab and Pertuzumab in HER2-Negative Breast Cancer Patients With Abnormal HER2 Signaling

Recruiting
2
64
US
Doxorubicin, Cyclophosphamide, Weekly Paclitaxel, Trastuzumab, Pertuzumab, Celcuity CELx HSF
NSABP Foundation Inc, Celcuity, LLC, Genentech, Inc.
HER2-negative Breast Cancer
10/23
10/23
PRISM, NCT03658525: Prostate Radiotherapy Integrated With Simultaneous MRI (The Study)

Recruiting
N/A
30
Europe
MR LINAC
Royal Marsden NHS Foundation Trust
Prostate Cancer
08/20
08/23
NCT06032663: Use of PET-MR in Head and Neck Cancer Patients - Diagnostic and Therapeutic Applications

Recruiting
N/A
10
Europe
PET-MRI
Sheffield Teaching Hospitals NHS Foundation Trust
Head and Neck Cancer
10/24
10/25
NCT01840293: Breast Cancer Proteomics and Molecular Heterogeneity

Recruiting
N/A
1780
Europe
Cancer Trials Ireland
Primary Breast Cancer, Recurrent/Metastatic Breast Cancer
12/29
01/38
Elliott, Martin
HR-NBL2, NCT04221035 / 2019-001068-31: High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)

Recruiting
3
800
Europe, RoW
Vincristine, L01CA02, Carboplatin, LO1XA02, Etoposide, L01CB01, Vindesine, L01CA03, Dacarbazine, L01AX04, Ifosfamide, Doxorubicin, L01DB01, Busulfan, L01AB01, Melphalan, L01AA03, Thiotepa, L01AC01, Radiotherapy, Dinutuximab Beta, L01XC16, Cisplatin, L01XA01, Temozolomide 100 MG, Irinotecan, Cyclophosphamid
Gustave Roussy, Cancer Campus, Grand Paris, PHRC, Solving Kids' Cancer Europe, Neuroblastoma UK, , BSPHO, Instituto de Investigación Sanitaria La Fe, Deutsche Krebshilfe
High-Risk Neuroblastoma, Patient With Insufficient Response Chemoimmunotherapy
11/26
11/32
DETERMINE, NCT05768178: Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.

Recruiting
2/3
30
Europe
Vemurafenib, Zelboraf, Cobimetinib, Cotellic
Cancer Research UK, University of Manchester, University of Birmingham, Royal Marsden NHS Foundation Trust, Hoffmann-La Roche
Solid Tumor, Haematological Malignancy, Melanoma, Thyroid Cancer, Papillary, Ovarian Neoplasms, Colorectal Neoplasms, Laryngeal Neoplasms, Carcinoma, Non-Small-Cell Lung, Glioma, Multiple Myeloma, Erdheim-Chester Disease, Thyroid Carcinoma, Anaplastic
10/29
10/29
CRUKD/21/004, NCT05722886: DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol

Recruiting
2/3
825
Europe
Alectinib, Alecensa, Atezolizumab, Tecentriq, Entrectinib, Rozlytrek, Trastuzumab in combination with pertuzumab, Herceptin in combination with Perjeta, Vemurafenib in combination with cobimetinib, Zelboraf in combination with Cotellic
Cancer Research UK, University of Manchester, University of Birmingham, Royal Marsden NHS Foundation Trust, Hoffmann-La Roche
Solid Tumor, Haematological Malignancy
10/29
10/29
DETERMINE, NCT05786716: Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Teenage/Young Adult and Paediatric Patients With Cancers With HER2 Amplification or Activating Mutations

Recruiting
2/3
30
Europe
Trastuzumab, Herceptin, Pertuzumab, Perjeta
Cancer Research UK, University of Manchester, University of Birmingham, Royal Marsden NHS Foundation Trust, Hoffmann-La Roche
Solid Tumor, Haematological Malignancy, Colorectal Neoplasms, Urinary Bladder Neoplasm, Gallbladder Neoplasms, Salivary Gland Neoplasm, Lung Neoplasm, Pancreatic Neoplasm, Ovarian Neoplasms, Prostatic Neoplasm, Skin Neoplasm
10/29
10/29
DETERMINE, NCT05770102: Trial Treatment Arm 02: Atezolizumab in Adult, Teenage/Young Adults and Paediatric Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition

Recruiting
2/3
30
Europe
Atezolizumab, Tecentriq
Cancer Research UK, University of Manchester, University of Birmingham, Royal Marsden NHS Foundation Trust, Hoffmann-La Roche
Malignancy, Malignant Neoplasm, Lymphoproliferative Disorders, Neoplasms by Histologic Type, Neoplasms by Site, Cancer, Colorectal Neoplasms, Endometrial Neoplasms, Melanoma
10/29
10/29
DETERMINE, NCT05770037: Trial Treatment Arm 01: Alectinib in Adult, Teenage/Young Adults (TYA) and Paediatric Patients With ALK Positive Cancers

Recruiting
2/3
30
Europe
Alectinib, Alecensa
Cancer Research UK, University of Manchester, University of Birmingham, Royal Marsden NHS Foundation Trust, Hoffmann-La Roche
Solid Tumor, Haematological Malignancy, Malignant Neoplasm, Lymphoproliferative Disorders, Neoplasms by Histologic Type, Neoplasms by Site, Cancer, Anaplastic Large Cell Lymphoma, Lymphoma, Renal Cell Carcinoma, Neuroblastoma
10/29
10/29
DETERMINE, NCT05770544: Trial Treatment Arm 03: Entrectinib in Adult, Teenage/Young Adults and Paediatric Patients With ROS1 Gene Fusion-positive Cancers.

Recruiting
2/3
30
Europe
Entrectinib, Rozlytrek
Cancer Research UK, University of Manchester, University of Birmingham, Royal Marsden NHS Foundation Trust, Hoffmann-La Roche
Solid Tumor, Haematological Malignancy, Malignancy, Malignant Neoplasm, Lymphoproliferative Disorders, Neoplasms by Histologic Type, Neoplasms by Site, Cancer, Brain Neoplasms, Melanoma, Glioma
10/29
10/29
Cairoli
CARTITUDE-6, NCT05257083: A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma

Recruiting
3
750
Europe, Canada, Japan, US, RoW
Daratumumab, Bortezomib, Lenalidomide, Dexamethasone, Cilta-cel, JNJ-68284528, Cyclophosphamide, Fludarabine
Stichting European Myeloma Network, Janssen Research & Development, LLC
Multiple Myeloma
06/33
08/40
SAKK 38/19, NCT04604067: Assessing a ctDNA and PET-oriented Therapy in Patients With DLBCL A Multicenter, Open-label, Phase II Trial.

Recruiting
2
260
Europe
Acalabrutinib
Swiss Group for Clinical Cancer Research
Diffuse Large B-cell Lymphoma
10/25
12/30
Cook
EMERALD, NCT05001737 / 2021-001577-24: Evaluate Efficacy, Safety and Tolerability, PK and PD of Emapalumab in Children and Adults With MAS in Still's or SLE

Active, not recruiting
3
41
Europe, Canada, Japan, US, RoW
Emapalumab, NI-0501, emapalumab-lzsg, ATC code: L04AA39 (WHO)
Swedish Orphan Biovitrum
Macrophage Activation Syndrome, Secondary Hemophagocytic Lymphohistiocytosis, Still Disease, Systemic Lupus Erythematosus, SJIA, AOSD, MAS
06/24
09/25
MajesTEC-4, NCT05243797 / 2021-002531-27: Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation

Recruiting
3
1572
Europe, Canada, RoW
Teclistamab, JNJ-64007957, Lenalidomide
Stichting European Myeloma Network, Janssen Pharmaceutica
Multiple Myeloma
04/28
04/32
CARTITUDE-6, NCT05257083: A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma

Recruiting
3
750
Europe, Canada, Japan, US, RoW
Daratumumab, Bortezomib, Lenalidomide, Dexamethasone, Cilta-cel, JNJ-68284528, Cyclophosphamide, Fludarabine
Stichting European Myeloma Network, Janssen Research & Development, LLC
Multiple Myeloma
06/33
08/40

Download Options